Form 4: Boston Scientific EVP John Bradley Sorenson Reports Stock Transactions

EVP of Global Operations at Boston Scientific, John Bradley Sorenson, reports transactions involving common stock and performance share units.

Summary

• John Bradley Sorenson, EVP of Global Operations at Boston Scientific, reported several transactions.
• On January 1, 2025, 4,469 performance share units were converted into common stock at a price of $0.00.
• Also on January 1, 2025, 2,127 shares were disposed of at $89.32 per share.
• On January 2, 2025, 4,119 shares were sold at $90.02 per share.
• A further 2,342 shares were sold on January 3, 2025, at an average price of $89.8587.
• These transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
• Following these transactions, Sorenson directly owns 32,977 shares of Boston Scientific common stock.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions, with no inherent positive or negative sentiment. It simply reflects the executive's trading activity.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company executive, providing transparency to investors regarding insider activity. It is a standard practice for publicly traded companies and their executives.

Comparison to Industry Standards

• Form 4 filings are standard practice across all publicly traded companies in the US and are mandated by the SEC.
• Executives at comparable medical device companies such as Medtronic and Abbott also routinely file Form 4s to report their stock transactions.
• The use of 10b5-1 trading plans is also a common practice among executives to avoid accusations of insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall impact is likely minimal given the volume of shares traded relative to the company's total outstanding shares.

Key Dates